An observational study in Respiration, Artificial and COVID-19, sponsored by Sanatorio Anchorena San Martin. Completed at 2 sites in Argentina. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-11-01.
Sponsored by Sanatorio Anchorena San Martin · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 127 studies in COVID-19 with a site in Argentina — 6 open to participants now, 7 under way, 5 of them phase 3. COVID-19 · Argentina.
Among the 127 studies in COVID-19 with a site in Argentina, this one is the 22nd largest by enrollment of the 40 observational ones that give a count, is one of 70 that started in 2020, is one of 40 observational ones, and was the 102nd registered.
7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.
Browse COVID-19 studies →6 of the 127 studies in COVID-19 with a site in Argentina are open now. Recruiting first, the newest first:
ModernaTX, Inc. · Sites in Argentina, United States, Dominican Republic and 3 more countries
Ages 6 mo–11 yrs · Healthy volunteers
Pfizer · Sites in Argentina, United States, Belgium and 15 more countries
Ages 18+
Pfizer · Sites in Argentina, United States, Belgium and 16 more countries
Ages 12+
Merck Sharp & Dohme LLC · Sites in Argentina, United States, Brazil and 21 more countries
Ages 18+
AstraZeneca · Sites in Argentina, United States, Australia and 36 more countries
Ages 18+
A study can be open while its sites in Argentina have not opened yet or have stopped. Only those recruiting at a site in Argentina →
Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
127 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 42 · Phase 3 54 · Phase 4 4
First in 2020; this study’s year is marked. 70 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 326 is above the median of 268 across 3,209 observational studies indexed under COVID-19.
Median enrollment 414 across the 87 interventional studies, 503 across the 40 observational. Of the 102 that completed or were terminated, 41 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
57 of 127 have an industry lead sponsor. The 10 most frequent:
Sanatorio Anchorena San Martin is the lead sponsor of 8 studies on the registry; 1 is open to participants now.
Sanatorio Anchorena San Martin has 3 studies filed under COVID-19 — fewer than ten, so there is no comparison to draw.
4 of the studies in COVID-19 with a site in Argentina that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT06679140Phase 3PfizerA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | 2027-10-01 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
| NCT03963622Unity Health TorontoCareful Ventilation in Acute Respiratory Distress Syndrome (COVID-19 and Non-COVID-19) | 2027-06 |
Add all 4 to your calendar (.ics) → With an account.
Among the 127 studies in COVID-19 with a site in Argentina, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This report is a multicenter, observational, analytical and prospective study. The objective was to describe the weaning of mechanical ventilation in patients with SARS-CoV-2 and the clinical results according to the different types of weaning.
This report is a multicenter, observational, analytical and prospective study.
Patients older than 18 years with a diagnosis of COVID-19 by PCR + and who required invasive VM for more than 12 hours from April 1 to August 30, 2020 were included. Subjects admitted to pediatric ICUs and in the recovery room were excluded. Patients who were readmitted and required a new cycle of MV after having been successfully weaned and released from the hospital were also excluded. All patients with data loss greater than 10% in variables considered clinically relevant were eliminated.
The weaning process from mechanical ventilation in each patient was classified by two strategies:
Definition of critical care medicine consensus conference published (2007) in:
Simple weaning: Patients successfully extubated after the first weaning attempt.
Difficult weaning: Patients who fail the first weaning attempt and require up to three spontaneous breathing trials or up to 7 days from the first spontaneous breathing trial to achieve a successful weaning.
Prolonged weaning: Patients who fail at least three weaning attempts or require more than 7 days after the first spontaneous breathing trial.
Definition of WIND study:
Group 0 ("no weaning"), made up of patients who never experienced any attempt to wean.
Group 1 (short weaning): the first attempt resulted in the completion of the weaning process in 1 day (successful weaning or early death).
Group 2 (difficult weaning): weaning was completed after more than 1 day but less than 1 week after the first attempt (successful weaning or death).
Group 3 (prolonged weaning): weaning is not yet completed 7 days after the first attempt (due to successful weaning or death).
The first attempt at weaning in intubated patients was considered as the performance of a spontaneous breathing trial with or without extubation, or extubation with or without SBT. In tracheostomized patients, the first period of spontaneous breathing (without ventilatory support) of at least 24 hours duration was considered as the first weaning attempt.
Weaning success was considered when death or re-intubation did not occur after extubation within 7 days or until discharge from the ICU (whichever occurs first), whether or not non-invasive ventilatory support was used. In tracheostomized patients, weaning was considered successful upon reaching seven consecutive days of spontaneous ventilation without ventilatory support or discharge from the ICU, whichever occurs first. [24]
The data were collected by the principal investigator of each center, or by one of the members of the work team designated for the study, preferably between 8:00 am and 11:00 am, recorded on paper sheets and dumped into a database " online "designed in REDCap (Research Electronic Data Capture) with software installed in the Centro del Parque clinic, Buenos Aires, Argentina, guaranteeing the protection and confidentiality of the data in accordance with the Declaration of Helsinki. Data were acquired from the moment of admission to the ICU (once the inclusion criteria and the absence of exclusion criteria had been met) and during the entire follow-up period. All members of the research group provided advice and support through direct telephone contact / e-mail specifically originated for the study.
Patients with a diagnosis of COVID-19 by PCR + and who required invasive mechanical ventilation for more than 12 hours were included.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
weaning rate
percentage of successfully weaned patients
Time frame: on day 28
weaning classification
number of spontaneous breathing tests and days from first spontaneous breathing test to success or death
Time frame: on day 28
mechanical ventilation days
duration of invasive mechanical ventilation
Time frame: on day 28
length of ICU stay
days of hospitalization in ICU
Time frame: on day 28
Ran from Apr 2020 to primary completion in Aug 2020, 4 months.
Of 1,640 non-industry observational studies under COVID-19, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 30. This study's 4 months is below that.
Counting every sponsor, half of 1,774 studies reached it within 13 months; a quarter within 5 and three quarters within 29.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sanatorio Anchorena San Martin